These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 30190472)

  • 1. The biological significance of histone modifiers in multiple myeloma: clinical applications.
    Ohguchi H; Hideshima T; Anderson KC
    Blood Cancer J; 2018 Aug; 8(9):83. PubMed ID: 30190472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
    Terui Y
    Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
    Dupéré-Richer D; Licht JD
    Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of epigenetic therapy in multiple myeloma.
    Smith EM; Boyd K; Davies FE
    Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.
    Amodio N; D'Aquila P; Passarino G; Tassone P; Bellizzi D
    Expert Opin Ther Targets; 2017 Jan; 21(1):91-101. PubMed ID: 27892767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells.
    Ciesielski O; Biesiekierska M; Balcerczyk A
    Molecules; 2020 May; 25(10):. PubMed ID: 32429384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease.
    Gordon JAR; Stein JL; Westendorf JJ; van Wijnen AJ
    Bone; 2015 Dec; 81():739-745. PubMed ID: 25836763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
    Maleszewska M; Kaminska B
    Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic regulation of memory by acetylation and methylation of chromatin: implications in neurological disorders, aging, and addiction.
    Sen N
    Neuromolecular Med; 2015 Jun; 17(2):97-110. PubMed ID: 24777294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acetyl code in rheumatoid arthritis and other rheumatic diseases.
    Angiolilli C; Baeten DL; Radstake TR; Reedquist KA
    Epigenomics; 2017 Apr; 9(4):447-461. PubMed ID: 28102705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting epigenetic DNA and histone modifications to treat kidney disease.
    Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
    Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic targeting for acute kidney injury.
    Zhuang S
    Nephrology (Carlton); 2018 Oct; 23 Suppl 4():21-25. PubMed ID: 30298650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.
    Ganesan A; Nolan L; Crabb SJ; Packham G
    Curr Cancer Drug Targets; 2009 Dec; 9(8):963-81. PubMed ID: 20025605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetics in cancer: targeting chromatin modifications.
    Ellis L; Atadja PW; Johnstone RW
    Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone onco-modifications.
    Füllgrabe J; Kavanagh E; Joseph B
    Oncogene; 2011 Aug; 30(31):3391-403. PubMed ID: 21516126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
    Wang F; Fischhaber PL; Guo C; Tang TS
    Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer.
    Gutiérrez JR; Salgado ARM; Arias MÁ; San-Juan-Vergara H; Rada WR; Gómez CMM
    Curr Med Chem; 2022; 29(9):1503-1542. PubMed ID: 34963430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromatin modifications remodel cardiac gene expression.
    Mathiyalagan P; Keating ST; Du XJ; El-Osta A
    Cardiovasc Res; 2014 Jul; 103(1):7-16. PubMed ID: 24812277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.